Dar? Bioscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 2834 darebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dar? Bioscience, Inc.

Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Mar 12th, 2026 6:00 am
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Mar 9th, 2026 6:25 am
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Mar 2nd, 2026 6:20 am
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Feb 23rd, 2026 6:00 am
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women - Feb 11th, 2026 6:00 am
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Jan 20th, 2026 3:48 am
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - Dec 10th, 2025 6:00 am
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - Dec 1st, 2025 6:00 am
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - Nov 24th, 2025 6:00 am
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Nov 13th, 2025 10:02 pm
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Nov 13th, 2025 3:10 pm
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 2:01 pm
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 3:30 pm
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health - Nov 11th, 2025 6:00 am
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - Nov 10th, 2025 6:25 am
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 4:25 pm
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - Nov 6th, 2025 6:00 am
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 3:10 pm
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates - Nov 4th, 2025 6:55 am
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Nov 3rd, 2025 6:00 am